ONLY ONE HAS 6X GREATER ACCURACY IN CONTACT FORCE SENSING*1,2
The TactiCath™ Quartz ablation catheter has proven greater accuracy in contact force sensing than ThermoCool SmartTouch‡ SF catheter.*1,2
CARDIOVASCULAR
The TactiCath™ Quartz ablation catheter enhances the ablation procedure by providing you with easy-to-understand measurements of the contact force (CF) applied between the catheter tip and the tissue surface.
The TactiCath™ Quartz ablation catheter has proven greater accuracy in contact force sensing than ThermoCool SmartTouch‡ SF catheter.*1,2
The main features of this unique ablation catheter include:
Designed for seamless integration, the TactiSys Quartz system is a plug-and-play system—eliminating the need for thermal calibrations. It also offers:
The TactiCath Quartz ablation catheter is one of our featured electrophysiology products. We are leading the way with inventive designs that give you the options you need to diagnose, treat and manage arrhythmias with versatility and effectiveness. When it comes to understanding and managing cardiac arrhythmias, we are your partner for life.
Read more about our approach to electrophysiology.
Product Manuals (Instructions for Use)
TactiCath Quartz Ablation Catheter Clinical Compendium
*In an independent head-to-head bench test comparison with the ThermoCool SmartTouch SF catheter, TactiCath Quartz contact force ablation catheter showed higher accuracy in both axial (perpendicular) and parallel (lateral) orientations.1
**This parameter was displayed during ablation procedures in a 31-patient supplemental study to the TOCCASTAR clinical trial. However, the clinical utility of this parameter has not been evaluated.
1. Bourier F, Deisenofer I, Hessling G, et al. (2016, May). Contact force sensing electrophysiological catheters: How accurate is the technology? [Abstract PO03-170]. Presented at HRS 2016, San Francisco, CA. Heart Rhythm. 2016;13(5 Suppl 1):S318-S319.
2. Bourier F, Gianni C, Dare M, et al. Fiberoptic Contact-Force Sensing Electrophysiological Catheters: How Precise Is the Technology? J Cardiovasc Electrophysiol. 2017 Jan;28(1):109-114.
3. Reddy, V., Shah, D., Kautzner, J., Schmidt, B., Saoudi, N., Herrera, C., … Kuck, K. H. (2012). The relationship between contact force and clinical outcome during radiofrequency catheter ablation of atrial fibrillation in the TOCCATA study. Heart Rhythm, 9(11), 1789-1795. http://dx.doi.org/10.1016/j.hrthm.2012.07.016
4. Neuzil, P., Reddy, V., Kautzner, J., Petru, J. Wichterle, D., Shah, D., … Kuck, K. H. (2013). Electrical reconnection after pulmonary vein isolation is contingent on contact force during initial treatment: Results from the EFFICAS I Study. Circulation: Arrhythmia and Electrophysiology, 6(2), 327-333. http://dx.doi.org/10.1161/CIRCEP.113.000374
5. Kautzner, J., Neuzil, P., Lambert, H., Peichl, P., Petru, J., Cihak, R., ... Kuck, K. H. (2015). EFFICAS II: Optimization of catheter contact force improves outcome of pulmonary vein isolation for paroxysmal atrial fibrillation. Europace, 17(8), 1229-1235. http://dx.doi.org/10.1093/europace/euv057
6. Mansour, M. (2014, May). TOCCASTAR: Preliminary results of the first prospective randomized study of a contact force sensing ablation catheter for the treatment of paroxysmal AF. Presented at the meeting of the Heart Rhythm Society, San Francisco, CA.
At Abbott, our goal is to advance the treatment of cardiac arrhythmias with innovations that improve both cost savings and clinical outcomes.
In an independent head-to-head bench test comparison with the ThermoCool SmartTouch SF catheter, TactiCath Quartz contact force ablation catheter showed higher accuracy in both axial (perpendicular) and parallel (lateral) orientations.10
Data from studies such as TOCCATA, EFFICAS I and EFFICAS II show that contact force (CF) sensing is not only safe for use in pulmonary vein isolation (PVI) but also associated with lower rates of PV reconnection and atrial fibrillation (AF) recurrence.1-4 As the cost of care has been reported to increase approximately four times in the first year after ablation for patients with repeat ablations, increased effectiveness of single ablation procedures for AF could substantially decrease health care costs for patients undergoing these procedures.8, 9
The purpose of the TOCCATA clinical trial was to evaluate the safety and efficacy of CF sensing during ablation procedures.1, 2
EFFICAS is a pair of studies to (I) identify and (II) validate CF recommendations to ensure pulmonary vein isolation.
Read more about the EFFICAS II study.
The TOCCASTAR trial (TactiCath Contact Force Ablation Catheter Study for Atrial Fibrillation) is the only prospective, randomized, controlled, multicenter study conducted to date to evaluate the safety and effectiveness of a contact force sensing ablation catheter for the treatment of symptomatic paroxysmal AF.5
Key Takeaways:
Read comprehensive information on these clinical studies:
TactiCath™ Quartz Ablation Catheter Clinical Compendium
A recent publication by Moussa Mansour et al. demonstrates that for patients undergoing repeat ablations, the cost of care increases approximately four times—to $52,821—in the first year after ablation and remained forty-six percent higher, even when excluding the cost associated with the additional ablation procedures.9
Another analysis showed that the use of optimal contact force guided AF ablationa with the TactiCath™ Quartz catheter resulted in fewer post ablation clinical events, translating to a 15-percent reduction in post ablation management costs ($3,402 savings per patient) in the year after ablation, compared with patients who were treated with a non-contact force ablation catheter.8
Read the article
© 2016 by the American College of Cardiology Foundation. Published by Elsevier.
The TactiCath Quartz ablation catheter is one of our featured electrophysiology products. As a leader in ablation and mapping technology, our vision is to transform the treatment of cardiac arrhythmias by designing outcome-driven and cost-effective technologies. Read more about our approach to electrophysiology.
Product Manuals (Instructions for Use)
TactiCath Quartz Ablation Catheter Clinical Compendium
‡Indicates a third party trademark, which is property of its respective owner.
a. Optimal CF contact defined as those patients where ≥ 90% lesions ≥ 10 g.
b. Nonoptimal CF contact defined as those patients where ˂ 90% lesions ≥ 10 g.
c. Clinically relevant success: no documented, symptomatic recurrence of atrial arrhythmia > 30 seconds (patient could use an AAD).
*In an independent head-to-head bench test comparison with the ThermoCool SmartTouch SF catheter, TactiCath Quartz contact force ablation catheter showed higher accuracy in both axial (perpendicular) and parallel (lateral) orientations.10
1. Kuck K. H., Reddy, V.Y., Schmidt, B., Natale, A., Neuzil, P. Saoudi, N., … Shah, D. C. (2012). A novel radiofrequency ablation catheter using contact force sensing: Toccata study. Heart Rhythm, 9(1), 18-23. http://dx.doi.org/10.1016/j.hrthm.2011.08.021
2. Reddy, V., Shah, D., Kautzner, J., Schmidt, B., Saoudi, N., Herrera, C., … Kuck, K. H. (2012). The relationship between contact force and clinical outcome during radiofrequency catheter ablation of atrial fibrillation in the TOCCATA study. Heart Rhythm, 9 (11), 1789-1795. http://dx.doi.org/10.1016/j.hrthm.2012.07.016
3. Neuzil, P., Reddy, V., Kautzner, J., Petru, J. Wichterle, D., Shah, D., … Kuck, K. H. (2013). Electrical reconnection after pulmonary vein isolation is contingent on contact force during initial treatment: Results from the EFFICAS I Study. Circulation: Arrhythmia and Electrophysiology, 6 (2), 327-333. http://dx.doi.org/10.1161/CIRCEP.113.000374
4. Kautzner, J., Neuzil, P., Lambert, H., Peichl, P., Petru, J., Cihak, R., … Kuck, K. (2015). EFFICAS II: optimization of catheter contact force improves outcome of pulmonary vein isolation for paroxysmal atrial fibrillation. Europace, 17(8), 1229-1235.
5. Reddy, V., Dukkipati, S., Neuzil, P., Natale, A., Albenque, J. Shah, D., … Mansour, M. (2015). Randomized controlled trial of the safety and effectiveness of a contact force sensing irrigated catheter for ablation of paroxysmal atrial fibrillation: Results of the TactiCath Contact Force Ablation Catheter Study for Atrial Fibrillation (TOCCASTAR) study. Circulation, 132 (10), 907-915. http://dx.doi.org/10.1161/CIRCULATIONAHA.114.014092. Optimal CF contact defined as those patients where ≥ 90% lesions ≥ 10 g. Nonoptimal CF contact defined as those patients where ˂90% lesions ≥ 10 g. Direct comparisons between studies are not possible due to differences between study methodology. Repeat ablation after the protocol defined 3-month blanking period, protocol defined success used for analysis.
6. Bourier, F., Gianni, C., Dare, M., Deisenhofer, I., Hessling, G., Reents, T., . . . Al-Ahmad, A. (2017). Fiberoptic contact-force sensing electrophysiological catheters: how precise is the technology? Journal of Cardiovascular Electrophysiology, 28(1), 109-114. http://dx.doi.org/10.1111/jce.13100
7. Natale, A., Reddy, V. Y., Monir, G., Wilber, D. J., Lindsay, B. D., McElderry, H. T., … Marchlinski, F. E. (2014) Paroxysmal AF catheter ablation with a contact force sensing catheter: Results of the prospective, multicenter SMART-AF trial. Journal of the American College of Cardiology, 19 (64), 647-656. http://dx.doi.org/10.1016/j.jacc.2014.04.072
8. Mansour, M. (2016, January). Contact force sensing in AF ablation: A health-economic analysis. Presented at the meeting of the AF Symposium, Orlando, FL
9. Mansour, M., Karst, E., Heist, E. K., Dalal, N., Wasfy, J. H., Packer, D. L., … Mahapatra, S. (2016). The impact of first procedure success rate on the economics of atrial fibrillation ablation. Journal of the American College of Cardiology: Clinical Electrophysiology. Available online 3 August 2016. http://dx.doi.org/10.1016/j.jacep.2016.06.002
10. Bourier F, Deisenofer I, Hessling G, et al. (2016, May). Contact force sensing electrophysiological catheters: How accurate is the technology? [Abstract PO03-170]. Presented at HRS 2016, San Francisco, CA. Heart Rhythm. 2016;13(5 Suppl 1):S318-S319
Using light interferometry, the TactiCath™ Quartz Catheter makes an interference analysis to compute both magnitude and orientation of contact force.
The intuitive display of contact force data allows for enhanced workflow. The EnSite™ contact force module shows the CF data on the EnSite Precision™ cardiac mapping system providing a single integrated display.
The TactiCath Quartz ablation catheter is also compatible with the following Abbott products:
The TactiCath Quartz ablation catheter is one of our featured electrophysiology products. As a leader in ablation and mapping technology, our vision is to transform the treatment of cardiac arrhythmias by designing outcome-driven and cost-effective technologies. Read more about our approach to electrophysiology.
Contact Force Ablation Catheter
Open-irrigated 7 F ablation catheter with 75 or 65 mm steerable curve
Reorder Number |
Description |
Curve |
French Size |
Electrode Spacing (mm) |
Tip Electrode (mm) |
Length (cm) |
PN-004 075 |
Irrigated Ablation Catheter (6 hole) |
75 |
7 |
2 - 5 - 2 |
3.5 |
115 |
PN-004 065 |
Irrigated Ablation Catheter (6 hole) |
65 |
7 |
2 - 5 - 2 |
3.5 |
115 |
TactiCath Quartz Ablation Catheter
Rx Only
Brief Summary: Prior to using these devices, please review the Instructions for Use for a complete listing of indications, contraindications, warnings, precautions, potential adverse events and directions for use.
Indications: The TactiCath Quartz Contact Force Ablation Catheter is indicated for use in cardiac electrophysiological mapping and for the treatment of drug refractory recurrent symptomatic paroxysmal atrial fibrillation, when used in conjunction with a compatible RF generator and three-dimensional mapping system.
Contraindications: Do not use for any of the following conditions: certain recent heart surgery; prosthetic valves; active systemic infection; use in coronary vasculature; myxoma or intracardiac thrombus, or an interatrial baffle or patch; retrograde trans-aortic approach in patients with aortic valve replacement.
Warnings: It is important to carefully titrate RF power; too high RF power during ablation may lead to perforation caused by steam pop. Contact force in excess of 70 g may not improve the characteristics of lesion formation and may increase the risk for perforation during manipulation of the catheter. Patients undergoing septal accessory pathway ablation are at risk for complete AV block which requires the implantation of a permanent pacemaker. Implantable pacemakers and implantable cardioverter/defibrillator may be adversely affected by RF current. Always verify the tubing and catheter have been properly cleared of air prior to inserting the catheter into the vasculature since entrapped air can cause potential injury or fatality. The temperature data transmitted by the sensor in this catheter is representative of the irrigated electrode only and does not provide tissue temperature data.
Precautions: The long-term risks of protracted fluoroscopy and creation of RF induced lesions have not been established; careful consideration must be given for the use of the device in prepubescent children. When using the catheter with conventional EP lab system or with a 3D navigational system, careful catheter manipulation must be performed, in order to avoid cardiac damage, perforation, or tamponade. Always maintain a constant saline irrigation flow to prevent coagulation within the lumen of the catheter. Access the left side of the heart via a transseptal puncture. Care should be taken when ablating near structures such as the sino-atrial and AV nodes.
Potential Adverse Events: Potential adverse events include, but are not limited to, cardiovascular related complications, including groin hematoma, pericardial effusion and infection. More serious complications are rare, which can include damage to the heart or blood vessels; blood clots (which may lead to stroke); tamponade; severe pulmonary vein stenosis; heart attack; esophageal fistula, or death. Please refer to the Instructions for Use for a complete list.
Dr. Moussa Mansour reveals the important economic benefit of
first-procedure success using TactiCath™ Quartz contact force ablation catheter in AF ablation.
SJM-CV WEB-0718-0026
Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.
The website that you have requested also may not be optimized for your screen size.
Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.
Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.
The website that you have requested also may not be optimized for your screen size.
Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.